News | December 30, 2022
Cipla EU to invest € 15 million in Ethris
Cipla and Ethris partner for the development of mRNA-based therapies
Cipla and Ethris partner for the development of mRNA-based therapies
The new facility will be able to handle four times as many patients as the previous facility.
This ambitious anti-TB campaign, as part of IOCL’s CSR, aims to ensure early identification of presumptive TB and prompt diagnosis using high-sensitivity diagnostic tests at the doorstep
The company has plans to launch this Vaccine by the end of 2023 after completing the required field studies and obtaining regulatory approvals
The vectored intranasal delivery platform gives us the capability for rapid product development, scale-up, easy and painless immunization during public health emergencies and pandemics
WHO made a strong recommendation for nirmatrelvir and ritonavir for mild and moderate COVID-19 patients at highest risk of hospital admission
Centre and states need to work in tandem and in a collaborative spirit as was done during the previous surges for COVID-19 prevention and management
The organisation is also working towards providing skills based training programmes to the workers for paramedical jobs and has launched certificate courses in ten disciplines
J. B. Chemicals & Pharmaceuticals has informed that the acquisition of the Razel franchise from Glenmark Pharmaceuticals Limited has been successfully completed.
Selexipag tablet is indicated in adults for the treatment of pulmonary arterial hypertension to delay disease progression and reduce the risk of hospitalization for PAH
Subscribe To Our Newsletter & Stay Updated
